Replimune Group, Inc.
RP1 (vusolimogene oderparepvec)
advanced melanoma
Resolved
88days ago
FDA decision · Apr 10, 2026
What's at stake
An FDA complete response letter on RP1 (vusolimogene oderparepvec) for advanced melanoma is in focus around Apr 10, 2026.
Primary source
· SEC 8-K
verified 14h ago
“On April 10, 2026, Replimune Group, Inc. (the “Company”) issued a news release announcing that the U.S. Food and Drug Administration (the “FDA”) has issued a second Complete Response Letter regarding the Biologics License Application (“BLA””